Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR--

WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ -- AstraZeneca today announced that two analyses from a large-scale study that investigated the efficacy of SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients, were presented today at the annual meeting of the American Psychiatric Association (APA). These analyses from the clinical trial data for SEROQUEL XR showed that it was effective versus placebo in patients with an acute exacerbation of symptoms of schizophrenia.(1,2)

On May 17, 2007, the U.S. Food and Drug Administration (FDA) approved SEROQUEL XR for the treatment of schizophrenia in adult patients.

"Both analyses show that SEROQUEL XR was superior to placebo, demonstrating it is another viable treatment option for schizophrenia," said Charles Schulz, MD, Professor and Head, Department of Psychiatry, University of Minnesota Medical School. "These analyses are significant because SEROQUEL XR may provide greater convenience and simplicity in patient treatment plans."

About large-scale study: Study 132

This six-week, double-blind, randomized, placebo-controlled study investigated the efficacy and safety of once-daily SEROQUEL XR. In this study, 588 patients with acute schizophrenia were randomized to receive either SEROQUEL XR at 400, 600, or 800 mg/day, the immediate release formulation of SEROQUEL(R) (quetiapine fumarate) at 400 mg/day (200 mg twice-daily), or placebo. The primary endpoint was assessed using the Positive and Negative Syndrome Scale (PANSS)(+).(1,2)

In the study, SEROQUEL XR was generally well-tolerated. SEROQUEL XR was administered once-daily at fixed doses, with dose escalation conducted over the initial three days (Day 1 = 300mg, Day 2 = 400 or 600mg, and Day 3=400, 600 or 800mg). The immediate release formul
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... York, NY (PRWEB) July 26, 2014 ... Infosecurity magazine on July 23rd, new research by Palo ... starting to rewrite their playbook, now focusing more on ... en masse who have become increasingly wise to their ... founder and CEO/CTO, Joe Caruso, talks about the ...
(Date:7/26/2014)... ON (PRWEB) July 26, 2014 Studio B ... type of implant, often called Teeth in a Day, gives ... with a full set of bright, pearly whites with very ... teeth are permanent, look and feel just like natural teeth, ... and regular checkups. Studio B Dental is one of ...
(Date:7/26/2014)... 2014 According to the Banish My ... a comprehensive guide that covers detailed instructions on how ... the need of any medication. , Vkool reveals ... and safe remedies for relieving symptoms of keratosis pilaris ...     How to treat children's keratosis pilaris ...
(Date:7/25/2014)... 26, 2014 PersonalInjurySolicitorsIreland, a legal ... to people who have suffered from a variety ... both their new company, and a website, ... new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law ... of the company is always on the client, ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2
... in diagnosing the condition, study says , , FRIDAY, Sept. 28 ... before, during or after pregnancy, a new study finds. , ... her baby and her entire family, according to the report ... of Psychiatry . , "The prevalence of women diagnosed with ...
... with important information on the use, of aspirin in the prevention ... ... strokes -, SILVER SPRING, Md., Sept. 28 Discovery Health ... and,secondary prevention of cardiovascular and cerebral-vascular events.,Premiering Sunday, September 30, at 9 ...
... Simcere,s Leading Position in China,s Stroke ... ... -- Simcere Pharmaceutical,Group (NYSE: SCR; "Simcere"), the manufacturer of the ... generic pharmaceuticals in China, today announced that it has,entered into ...
... for Medical Equipment/Healthcare IT, Facility Design Consulting, Building ... and NEW YORK, Sept. 28 ,Susquehanna Health has ... range,of technology and service solutions for a master ... Valley Hospital, Divine,Providence Hospital, Hepburn Plaza and The ...
... GOLDEN, Colo., Sept. 28 ABR-Affinity,BioReagents, a ... an expanded 100% Quality Guarantee. Launched ... was,established to bolster confidence in research antibodies. ... building blocks of early-stage life science,research and ...
... With audience members cheering and,famous Chicago chefs watching their ... the finalists at Consorta,s Battle of the Hospital,Chefs. ... organic cucumbers he,serves the patients at Saint Mary,s Health ... Gold Chef Award, becoming the reigning champion of,chefs among ...
Cached Medicine News:Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 2Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 3Health News:Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits 4Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 2Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 3Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 4Health News:Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment 2Health News:Susquehanna Health and Siemens Announce Plans to Improve Hospital Facilities Through Technology Investment 3Health News:ABR-Affinity BioReagents Expands 100% Quality Guarantee 2Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: